ABOUT MINORYX

ABOUT MINORYX

At Minoryx, we are committed to finding innovative treatments for life threatening rare diseases.

Marc Martinell, PhDCo-Founder & Chief Executive Officer

Minoryx is a clinical stage biotech company leading the development of new therapies for X-ALD and other Orphan CNS diseases, a group of rare diseases of genetic origin with a high unmet medical need. The company’s leading program, a differentiated PPAR gamma agonist (MIN-102), is a candidate for X-linked Adrenoleukodystrophy that has successfully completed phase 1 clinical trials and is now in a pivotal phase 2/3 trial. Minoryx harnesses its unique mechanism of action for potential use in X-ALD, a genetic disease characterized by progressive neurological deterioration with no available pharmacological treatment.

Minoryx is also working on expanding the use of MIN-102 into other CNS diseases.

All our activities are performed under an ethical code which is driven by the following values:

Commitment:

One of the biggest assets of the company is our team, a group of professionals fully committed to the task of delivering new treatments for rare diseases.

Social responsibility:

Minoryx and their employees are absolutely dedicated to relieving people’s suffering from rare diseases, especially children and their families.

Innovation & Dynamism:

We innovate by exploiting state of the art technologies. We form synergistic partnerships for drug discovery and provide them with an environment which fosters creativity and open-mindedness.

Added Value:

We strive to provide life-changing treatments for diseases with highly unmet medical needs.

This website uses our own and third party Cookies to gather information in order to improve our services. If you continue browsing, it means accepting the installation of the same. The user has the possibility of configuring his browser and can, if he wishes, prevent them from being installed on his hard disk, although he must bear in mind that such action may cause navigation difficulties of the web page. How to set up